SCHEMBL10073790

SCHEMBL10073790

Cc1cc(Oc2ccc(NC(=O)Nc3ccccc3)cc2)c[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.54
CA1 P00915 3/20 0.54
CA2 P00918 3/20 0.54
CA9 Q16790 3/20 0.54
RAF1 P04049 2/20 0.52
HPGD P15428 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TP53 P04637 1/20 0.51
TSHR P16473 1/20 0.51
CDK8 P49336 3/20 0.51
KDR P35968 2/20 0.50
MEN1 O00255 2/20 0.50
LMNA P02545 2/20 0.50
MAPT P10636 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 1/20 0.50
CRHBP P24387 1/20 0.50
RAB9A P51151 1/20 0.50
CRHR2 Q13324 1/20 0.50
IDH1 O75874 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717145 0.82 HSD17B10 (0.51) HPGDSMN1; SMN2CDK8NPC1CRHBP
SCHEMBL12362188 0.81 SMN1; SMN2 (0.63) CA12CA1CA2CA9HPGD
SCHEMBL21295380 0.81 CA12 (0.71) CA12CA1CA2CA9HPGD
SCHEMBL18236215 0.80 SMN1; SMN2 (0.61) SMN1; SMN2TP53TSHRMEN1LMNA
SCHEMBL30053559 0.79 CA12 (0.73) CA12CA1CA2CA9HPGD
SCHEMBL282051 0.79 CDK8 (0.65) RAF1CDK8KDR
SCHEMBL12994776 0.79 HPGD (0.65) CA12CA1CA2CA9HPGD
SCHEMBL21295338 0.78 TP53 (0.83) CA12CA1CA2CA9RAF1
SCHEMBL10192075 0.78 KMT2A (0.71) CA12CA1CA2CA9RAF1
SCHEMBL282086 0.78 RAF1 (0.60) RAF1SMN1; SMN2CDK8KDRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 CA12 93/4885CA1 178/4885CA2 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.